Testing secukinumab for severe Takayasu arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial tests a medication called secukinumab for people with active, severe Takayasu arteritis, a disease that causes inflammation in large blood vessels. The goal is to see if secukinumab can help control the disease better than standard treatments alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years old or older.
- You have been diagnosed with active, severe Takayasu arteritis, a condition where your large blood vessels are inflamed.
- Your disease is still active despite treatment with steroids or other immunosuppressants, or you have serious blood vessel problems (like stroke, vision loss, or blocked arteries).
- You are willing to take prednisone (a steroid) at a dose between 10 and 50 mg per day at the start of the study.
- You do not have active infections (like tuberculosis, HIV, or hepatitis B) and have not received a live vaccine in the last 3 months.
- You are not pregnant, breastfeeding, and if you could become pregnant, you agree to use highly effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This trial tests whether pirfenidone, a medication used for lung scarring, can reduce scarring (fibrosis) in the arteries of people with Takayasu arteritis. It aims to slow disease progression and improve blood vessel health.
This UK-based study uses a questionnaire to learn about how people with Takayasu arteritis (a rare type of vasculitis) are treated and what they think about their care. If you have TAK, your answers can help doctors understand how to better manage this condition.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.